Literature DB >> 10980598

Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.

K Kiguchi1, D Bol, S Carbajal, L Beltrán, S Moats, K Chan, J Jorcano, J DiGiovanni.   

Abstract

The erbB family of receptor tyrosine kinases, which consists of the epidermal growth factor receptor (EGFr/erbB1), erbB2 (neu), erbB3 and erbB4, has been shown to be important for both normal development as well as neoplasia. The expression of rat erbB2 was targeted to the basal layer of mouse epidermis with the bovine keratin 5 promoter. Overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with >90% incidence by 6 months. Analysis of several proliferation/differentiation markers indicated that erbB2 overexpression led to epidermal hyperproliferation and a possible delay in epidermal differentiation. Transgenic mice were also hypersensitive to the proliferative effects of the skin tumor promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA) and were more sensitive to two-stage carcinogenesis. Elevations in EGFr and erbB2 protein as well as erbB2:EGFr and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgenic mice. Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. These results indicate an important role for erbB2 signaling in epidermal growth, development and neoplasia. Oncogene (2000) 19, 4243 - 4254

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980598     DOI: 10.1038/sj.onc.1203778

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 2.  Asymmetric cell divisions in the epidermis.

Authors:  Nicholas D Poulson; Terry Lechler
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

3.  Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.

Authors:  Kaoru Kiguchi; Takuya Kitamura; Tricia Moore; Mohammad Rumi; Hsiang-Chun Chang; Devon Treece; Lynnsie Ruffino; Kevin Connolly; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-03

Review 4.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 5.  Genetically modified laboratory mice with sebaceous glands abnormalities.

Authors:  Carmen Ehrmann; Marlon R Schneider
Journal:  Cell Mol Life Sci       Date:  2016-07-25       Impact factor: 9.261

6.  Cbl-3-deficient mice exhibit normal epithelial development.

Authors:  Emily K Griffiths; Otto Sanchez; Pleasantine Mill; Connie Krawczyk; Carlo V Hojilla; Evelyn Rubin; Marion M Nau; Rama Khokha; Stan Lipkowitz; Chi-Chung Hui; Josef M Penninger
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 7.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

8.  Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.

Authors:  Eran R Andrechek; William R Hardy; Michael A Laing; William J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

9.  Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.

Authors:  Katie Ridd; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

10.  Overexpression of epigen during embryonic development induces reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia.

Authors:  Maik Dahlhoff; Daniela Frances; Jennifer E Kloepper; Ralf Paus; Matthias Schäfer; Catherin Niemann; Marlon R Schneider
Journal:  Mol Cell Biol       Date:  2014-06-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.